Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential

References

• AhrenBGomisRStandlE2004Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetesDiabetes Care2728748015562200
   PubMed Web of Science ®Google Scholar
• AhrenB2008Novel combination treatment of type 2 diabetes: DPP-4 inhibition + metforminVasc Health Risk Manag438294
   Google Scholar
• AschnerPKipnesMSLuncefordJK2006Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetesDiabetes Care292632717130196
   PubMed Web of Science ®Google Scholar
• AzumaKRadikovaZMancinoJ2008Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetesJ Clin Endocrinol Metab934596418042650
   PubMed Web of Science ®Google Scholar
• BolenSFeldmanLVassyJ2007Systemic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitusAnn Intern Med1473869917638715
   PubMed Web of Science ®Google Scholar
• BuddeKNeumayerHFritscheL2003The pharmacokinetics of pioglitazone in patients with impaired renal functionBr J Clin Pharmacol553687412680885
   PubMed Web of Science ®Google Scholar
• ChanJCScottRFerreiraA2008Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiencyDiabetes Obes Metab105455518518892
   PubMed Web of Science ®Google Scholar
• DormandyJACharbonnelBEcklandDJA2005Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macrovascular Events): a randomized controlled trialLancet36612798916214598
   PubMed Web of Science ®Google Scholar
• DruckerDJNauckMA2006The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet368169670517098089
   PubMed Web of Science ®Google Scholar
• GarberAJSchweizerABaronA2007Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled studyDiabetes Obes Metab91667417300592
   PubMed Web of Science ®Google Scholar
• GarberAJFoleyJEBanerjiA2008Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulfonylureaDiabetes Obes Metab [Epub ahead of print]
   Google Scholar
• GokeBHershonKKerrD2008Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metforminHorm Metab Res [Epub ahead of print]
   Google Scholar
• GoldsteinBJFeinglosMNLuncefordJK2007Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetesDiabetes Care30197987 Erratum: Diabetes Care, 2008; 31: 171317485570
   PubMed Web of Science ®Google Scholar
• HanefeldMHermanGAWuM2007Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetesCurr Med Res Opin231329133917559733
   PubMed Web of Science ®Google Scholar
• Januvia® (sitagliptin phosphate) package insert2007Merk and Co., IncWhitehouse Station, NJ 08889, USA
   Google Scholar
• KermaniAGargA2003Thiazolidinedione-associated congestive heart failure and pulmonary edemaMayo Clin Proc7810889112962163
   PubMed Web of Science ®Google Scholar
• ManleyHJAllockNM2003Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysisPharmacotherpay238615
   PubMed Web of Science ®Google Scholar
• MikhailN2006Exenatide: a novel approach for treatment of type 2 diabetesSouth Med J991271917195423
   PubMed Web of Science ®Google Scholar
• MikhailNCopeD2007The role of DPP-4 inhibitors in type 2 diabetesPatient Care81824
   Google Scholar
• MikhailN2008Incretin mimetics and dipeptidyl peptidase inhibitors in clinical trials for the treatment of type 2 diabetesExpert Opin Investig Drugs1784553
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonM2006Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapyDiabetes Care2919637216873813
   PubMed Web of Science ®Google Scholar
• NauckMAMeiningerGShengDfor the Sitagliptin Study 024 Group2007Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trialDiabetes Obes Metab919420517300595
   PubMed Web of Science ®Google Scholar
• Pi-SunyerFXSchweizerAMillsD2007Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetesDiabetes Res Clin Pract76132817223217
   PubMed Web of Science ®Google Scholar
• PratleyREJauffret-KamelSGalbreathE2006Twelve-week mono-therapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetesHorm Metab Res38423816823726
   PubMed Web of Science ®Google Scholar
• RazIHanefeldMXuLfor the Sitagliptin Study 023 Group2006Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia4925647117001471
   PubMed Web of Science ®Google Scholar
• RosenstockJBrazgRAndryukPJfor the Sitagliptin Study 019 Group2006Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyClin Ther2815566817157112
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMACamisascaRP2007Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetesDiabetes Obes Metab91758517300593
   PubMed Web of Science ®Google Scholar
• UtzschneiderKMTongJMontgomeryB2008The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucoseDiabetes Care311081317909087
   PubMed Web of Science ®Google Scholar
• VellaABockGGieslerPD2007Effects of dipeptidyl peptidase inhibition on gastrointestinal function, meal appearanace, and glucose metabolism in type 2 diabetesDiabetes5614758017303799
   PubMed Web of Science ®Google Scholar
• VilsbollTAgersoHKrarupT2003Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjectsJ Clin Endocrinol Metab88220412519856
   PubMed Web of Science ®Google Scholar
• Yki-JarvinenH2004Drug therapy: ThiazolidinedionesN Engl J Med35111061815356308
   PubMed Web of Science ®Google Scholar